Skip to main content
Top
Published in: Virology Journal 1/2015

Open Access 01-12-2015 | Research

Standardization of the methods and reference materials used to assess virus content in varicella vaccines

Authors: JiYoung Hong, Ho Jung Oh, Naery Lee, Do-Keun Kim, Heui-Seong Yoon, Yeon-Tae Kim, Seokkee Chang, Jae-Hak Park, Hyejoo Chung

Published in: Virology Journal | Issue 1/2015

Login to get access

Abstract

Background

In Korea, every vaccine lot is tested by the National Center for Lot Release (NCLR) in accordance with the national lot release procedures to ensure the safety and efficacy of vaccines. These quality tests examine the virus content in varicella vaccines via plaque assays (either the agar overlay method [AOM] or plaque staining method [PSM]), according to the procedures suggested by the Korean Reference Material for the Varicella Vaccine (KRMVV) or the manufacturer’s standard in-house protocol.

Aim

To standardize the virus content tests, viral titers in the KRMVV were measured using the PSM at four participating laboratories in a collaborative study. With the aim of developing a standardized method using the KRMVV as a positive control, we compared the ability of the two test methods, AOM and PSM, to accurately and reproducibly determine the virus content of two commercial varicella vaccines.

Results

The results showed that the standardized method (PSM) was more suitable for quality control analysis of the varicella vaccine.

Conclusion

Use of a standardized method (PSM) according to the Korean reference material will improve the reliability and objectivity of lot release testing.
Literature
1.
go back to reference Sheffer R, Segal D, Rahamani S, Dalal I, Linhart Y, Stein M. Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel. Pediatr Infect Dis J. 2005;24:434–7.PubMedCrossRef Sheffer R, Segal D, Rahamani S, Dalal I, Linhart Y, Stein M. Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel. Pediatr Infect Dis J. 2005;24:434–7.PubMedCrossRef
2.
go back to reference Unim B, Saulle R, Boccalini S, Taddei C, Ceccherini V, Boccia A, et al. Economic evaluation of varicella vaccination (Results of a systematic review). Hum Vaccin Immunother. 2013;9:1932–42.PubMedCentralPubMedCrossRef Unim B, Saulle R, Boccalini S, Taddei C, Ceccherini V, Boccia A, et al. Economic evaluation of varicella vaccination (Results of a systematic review). Hum Vaccin Immunother. 2013;9:1932–42.PubMedCentralPubMedCrossRef
3.
go back to reference Vázquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001;344:955–60.PubMedCrossRef Vázquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001;344:955–60.PubMedCrossRef
4.
go back to reference Takahashi M. 25 years’ experience with the Biken Oka strain varicella vaccine: a clinical review. Paediatr Drugs. 2001;3:285–92.PubMedCrossRef Takahashi M. 25 years’ experience with the Biken Oka strain varicella vaccine: a clinical review. Paediatr Drugs. 2001;3:285–92.PubMedCrossRef
5.
go back to reference Quinlivan M, Breuer J. Clinical and molecular aspects of the live attenuated Oka varicella vaccine. Rev Med Virol. 2014;24:254–73.PubMedCrossRef Quinlivan M, Breuer J. Clinical and molecular aspects of the live attenuated Oka varicella vaccine. Rev Med Virol. 2014;24:254–73.PubMedCrossRef
6.
go back to reference Sadzot-Delvaux C, Rentier B, Wutzler P, Asano Y, Suga S, Yoshikawa T, et al. Varicella vaccination in Japan, South Korea, and Europe. J Infect Dis. 2008;197:S185–190.PubMedCrossRef Sadzot-Delvaux C, Rentier B, Wutzler P, Asano Y, Suga S, Yoshikawa T, et al. Varicella vaccination in Japan, South Korea, and Europe. J Infect Dis. 2008;197:S185–190.PubMedCrossRef
7.
8.
go back to reference Heider H, Schroeder C. Focus luminescence assay: macroscopically visualized foci of human cytomegalovirus and varicella zoster virus infection. J Vriol Methods. 1997;66:311–6.CrossRef Heider H, Schroeder C. Focus luminescence assay: macroscopically visualized foci of human cytomegalovirus and varicella zoster virus infection. J Vriol Methods. 1997;66:311–6.CrossRef
9.
go back to reference Krah DL, Schofield TL, Provost PL. Enhancement of varicella-zoster virus plaquing efficiency with an agarose overlay medium. J Virol Methods. 1990;27:319–26.PubMedCrossRef Krah DL, Schofield TL, Provost PL. Enhancement of varicella-zoster virus plaquing efficiency with an agarose overlay medium. J Virol Methods. 1990;27:319–26.PubMedCrossRef
10.
go back to reference Kim JI, Jung GS, Kim YY, Ji GY, Kim HS, Wang WD, et al. Sequencing and characterization of Varicella-Zoster virus vaccine strain Suduvax. Virol J. 2011;8:547.PubMedCentralPubMedCrossRef Kim JI, Jung GS, Kim YY, Ji GY, Kim HS, Wang WD, et al. Sequencing and characterization of Varicella-Zoster virus vaccine strain Suduvax. Virol J. 2011;8:547.PubMedCentralPubMedCrossRef
11.
go back to reference Kim YH, Kim DK, Sohn YW, Han ER, Lim JM, Kim KH, et al. Manufacturing and establishment of the 2nd national standard for varicella vaccine. Korean Soci Biotech Bioengineer Journal. 2010;25:572–6. Kim YH, Kim DK, Sohn YW, Han ER, Lim JM, Kim KH, et al. Manufacturing and establishment of the 2nd national standard for varicella vaccine. Korean Soci Biotech Bioengineer Journal. 2010;25:572–6.
12.
go back to reference Quinlivan M, Breuer J. Molecular studies of varicella zoster virus. Rev Med Virol. 2006;16:225–50.PubMedCrossRef Quinlivan M, Breuer J. Molecular studies of varicella zoster virus. Rev Med Virol. 2006;16:225–50.PubMedCrossRef
13.
go back to reference Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study. Vaccine. 2014;32:1745–53.PubMedCrossRef Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study. Vaccine. 2014;32:1745–53.PubMedCrossRef
14.
go back to reference Mullane KM, Winston DJ, Wertheim MS, Betts RF, Porstz DM, Camacho LH, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013;208:1375–85.PubMedCrossRef Mullane KM, Winston DJ, Wertheim MS, Betts RF, Porstz DM, Camacho LH, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013;208:1375–85.PubMedCrossRef
Metadata
Title
Standardization of the methods and reference materials used to assess virus content in varicella vaccines
Authors
JiYoung Hong
Ho Jung Oh
Naery Lee
Do-Keun Kim
Heui-Seong Yoon
Yeon-Tae Kim
Seokkee Chang
Jae-Hak Park
Hyejoo Chung
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2015
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-015-0333-1

Other articles of this Issue 1/2015

Virology Journal 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.